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Low-dose versus high-dose ﬁsh oil for pain
reductionQ1
¶
and function improvement in
patients with knee osteoarthritisN1
¶N2
¶ Osteoarthritis (OA) is one of the leading generators of musculo-
skeletal pain and the main cause of disability.1 It has been con-
sidered an inﬂammatory disease with low grade inﬂammation
affecting the synovium, cartilage and subchondral bone.2 To
date, there is no disease-modifying OA drug.3 A few studies
have evaluated the efﬁcacy of ﬁsh oil in the treatment of OA4;
nevertheless, the effectiveness and precise beneﬁts of ﬁsh oil
intake in patients with OA are still far from well understood.
We read with deep interest a recent article published in this
journal by Hill et al, who found signiﬁcant improvement of OA
pain and function after treatment by ﬁsh oil, and suggested that
the low-dose ﬁsh oil group had much better improvement in
pain and function at 2 years in comparison to the high-dose
one.5 The authors are congratulated for the excellent ﬁndings
and we really appreciate the work performed by them; never-
theless, some worthwhile issues need further exploration.
First of all, this study was designed without a placebo treat-
ment group. The placebo control is used to account for the
placebo effect, and it is required in a large number of clinical
trials.6 7 The authors explained that “It was considered uneth-
ical to prevent ﬁsh oil supplements for 2 years in these partici-
pants”.5 This is understandable. Nevertheless, since the efﬁcacy
of ﬁsh oil versus placebo in the treatment of knee OA is still
unclear, we are not sure whether it is appropriate to conduct a
clinical trial without placebo control to examine the anti-
inﬂammatory efﬁcacy of ﬁsh oil for knee OA, and to address
that the pain scores in this study were ‘comparable to those seen
with placebo effect for pain’.5
Second, the patient recruitment and completion of this study
was not clearly described. The authors stated that some patients
in both groups were withdrawn from therapy at Year 1 and Year
2, but not all these withdrawn patients were excluded from
study assessment.8 Additionally, the sample size for analysis at
Year 2 in the low-dose group was 85 after 3 patients were with-
drawn from 90 patients at Year 1. However, the reasons for
these issues were not addressed. These changes may have led to
the bias of the results.
Third, the objective of the study was to compare the effects
of an anti-inﬂammatory dose of ﬁsh oil with a lower dose of
ﬁsh oil in knee OA.8 We fully agree with the authors that the
OA joint inﬂammation can be partly reﬂected through the evalu-
ation of bone marrow lesions by MRI, but we have no idea why
the authors did not use MRI to assess synovitis, which is a hall-
mark of joint inﬂammation and closely related to joint pain and
function in OA.9 In addition, the evaluation of proinﬂammatory
cytokines which contribute to OA pathogenesis, such as inter-
leukin 1β and TNF,2Q2
¶
was not performed in the study. On the
other hand, knee pain was selected as a parameter of OA inﬂam-
mation in this study, but a substantial part of knee pain might
result from other musculoskeletal diseases and the authors had
not screened for these conditions. It was further noted that par-
ticipants were provided with paracetamol tablets and were told
that they could safely use up to eight per day. Is it possible that
the patients with more severe joint pain have used more para-
cetamol tablets? Nevertheless, the authors then found that there
was no difference between the two groups in the use of para-
cetamol or NSAIDs. The underlying mechanism would be inter-
esting for further discussion.
Finally, the authors did not describe whether any other OA
treatments were offered to the patients during the follow-up
period, such as acupuncture, glucosamine, and intra-articular
hyaluronan or steroid injection. Also high rates of serious
adverse events (ie, non-elective hospital admissions) were found
in both treatment groups and the detailed causes were missing.
Some of the patients were reported to take knee surgery; it
would be interesting to know more details of the surgery and
whether the surgery had inﬂuenced the pain and the function
assessment. Additionally, some other confounders may need to
be addressed, such as the exercise type and intensity, occupation,
alcohol-drinking status, smoking-status, diabetes mellitus, etc.
We respect the great contributions of the authors and we
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